|
English
|
正體中文
|
简体中文
|
2823024
|
|
???header.visitor??? :
30248034
???header.onlineuser??? :
977
???header.sponsordeclaration???
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"reckamp k l"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
臺大學術典藏 |
2022-08-10T02:37:39Z |
Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study
|
Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. |
國立成功大學 |
2021 |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
Yang, J.C.-H.;Reckamp, K.L.;Kim, Y.-C.;Novello, S.;Smit, E.F.;Lee, J.-S.;Su, W.-C.;Akerley, W.L.;Blakely, C.M.;Groen, H.J.M.;Bazhenova, L.;Carcereny, Costa E.;Chiari, R.;Hsia, T.-C.;Golsorkhi, T.;Despain, Despain D.;Shih, D.;Popat, S.;Wakelee, H. |
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
|